About Biologicas Canarias
Biologicas Canarias is a company based in Valencia (Spain) founded in 1999 was acquired by De Sangosse in September 2018. Biologicas Canarias operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Valencia, Spain
- SectorsHealthcareAgriculture
- Email••••••••
- Phone•••• ••••
- Website biolcan.com
- Social Facebook
- Acquired by De Sangosse (Sep 2018)
- Investors
- Acquired byDe Sangosse
(Sep 2018)
Investors in Biologicas Canarias
Biologicas Canarias has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include De Sangosse.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Crop protection and nutrition products are manufactured and supplied internationally. | 1926 | desangosse.com | - |
Investor details for Biologicas Canarias
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Biologicas Canarias
2 dated milestones of Biologicas Canarias across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Biologicas Canarias is founded.
- Exit Acquired by De Sangosse.
Competitors of Biologicas Canarias
Biologicas Canarias operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of Biologicas Canarias
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Biologicas Canarias
Websites that share an audience with Biologicas Canarias (biolcan.com).
Websites whose visitors overlap most with Biologicas Canarias. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
basf.es | basf.es | 100% | – | #2,417,995 | – |
| daymsa.com | 100% | 3.3K | #4,977,689 | View details | |
| herogra.es | 100% | – | – | View details | |
tradecorp.com.es | tradecorp.com.es | 100% | – | – | – |
| econatur.net | 100% | – | #3,336,358 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for Biologicas Canarias
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Similar companies to Biologicas Canarias
10 companies that operate in the same segment as Biologicas Canarias (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Biologicas Canarias
Biologicas Canarias was founded in 1999.
Biologicas Canarias is headquartered in Valencia, Spain. It is registered at Valencia, Valencian Community, Spain.
Biologicas Canarias was founded in 1999 in Valencia, Spain, within the agricultural biotechnology sector. Biofertilizers and natural biostimulants are produced by isolating and applying beneficial microorganisms to create non-polluting solutions. The product range encompasses biofertilizers, biostimulants, seaweed extracts, foliar fertilizers, and related items. Operations focus on sustainable agricultural inputs distributed primarily in Europe.
Biologicas Canarias's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Biologicas Canarias has 1 investor. Key investors include De Sangosse.
Yes. Biologicas Canarias was acquired by De Sangosse in September 2018.